glp-1 clinical trial Real-World Evidence for Receptor Agonists Across the CKD Spectrum – AJKD Blog Issue 42: GLP-1 RA Drug
Description
Effect of weight loss on cardiometabolic risk: observational analysis of two randomised controlled trials of community weight-loss programmes
95% CI, 0.38 to 1.16
Create Account Already have an account
But they can also create echo chambers where risk normalization occurs gradually
GLP-1 agonists have already transformed the treatment landscape for diabetes and obesity, and their potential role in addiction medicine represents an exciting new frontier
KEY OBSERVATIONS Pomegranate holds active LegitScript certification
